Danvers, MA January 11, 2023
Cell Signaling Technology (CST) announced today it has entered into a new license agreement with Roche to support companion diagnostic (CDx) development. Roche is the global market leader in CDx immunoassays, and this agreement will allow for the development and commercialization of CDx assays using CST antibodies.
This agreement provides a framework to further facilitate the use of best-in-class CST products throughout the pharma development workflow. CST is positioned to enable pharma partners along the path of discovery through CDx development. This agreement further supports CST's pharma engagement strategy and demonstrates CST’s commitment to driving drug development forward.
"CST is excited to further support our pharma partners through enabling the critical translation of research and pre-clinical applications into CDx assays. Reproducibility and antibody specificity are the cornerstones that ideally position CST to support the advancement of biotherapeutics to the clinic. Our partnership with Roche shows how CST is committed to forming bridges to help advance new cures to devastating diseases,” said Roberto Polakiewicz, Cell Signaling Technology, Chief Scientific Officer.
Cell Signaling Technology (CST) is a different kind of life sciences company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 400 people worldwide. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. CST is a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our Customers, our communities, and our planet. cellsignal.com
CST Media and Press
Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Senior Director, Global MarComm & Technology
Phone: 978-880-3334
email: [email protected]
